{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:59:51Z","timestamp":1773284391048,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273424"],"award-info":[{"award-number":["81273424"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170862"],"award-info":[{"award-number":["81170862"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science and Technology Major Projects of the Twelfth Five-year Plan","award":["2011ZX09302-007-02"],"award-info":[{"award-number":["2011ZX09302-007-02"]}]},{"name":"Shanghai Key Laboratory of Ocular Fundus Diseases"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Macular oedema secondary to central retinal vein occlusion is a major cause of vision loss. Intraocuclar anti\u2010vascular endothelial growth factor injection is a promising treatment but lacks clinical evidence of its safety and efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Meta\u2010analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Patients from previously reported randomized, controlled trials comparing intravitreal anti\u2010vascular endothelial growth factor <jats:italic>versus<\/jats:italic> sham injections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search in <jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>, <jats:styled-content style=\"fixed-case\">CENTRAL<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content> was conducted for reports published by <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>pril 2013. A meta\u2010analysis of the retrieved data was conducted in <jats:styled-content style=\"fixed-case\">RevMan<\/jats:styled-content> 5.2 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>Primary outcome measures were changes in best\u2010corrected visual acuity and central retinal thickness from baseline. Secondary outcome measures were the proportion of eyes changing 15 or more letters on the <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>arly <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>reatment in <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>iabetic <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>etinopathy <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tudy chart, the proportion with neovascularization and changes in the 25\u2010item Visual Function Questionnaire. Severe adverse events were summarized to assess safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six trials involving a total of 940 eyes were included in the meta\u2010analysis. The mean difference in 6\u2010month changes in best\u2010corrected visual acuity and central retinal thickness for the anti\u2010vascular endothelial growth factor group were 15.2 <jats:styled-content style=\"fixed-case\">E<\/jats:styled-content>arly <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>reatment <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>iabetic <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>etinopathy <jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>tudy letters (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009&lt;\u20090.00001) and \u2212242.2\u2009\u03bcm (<jats:italic><jats:styled-content style=\"fixed-case\">P<\/jats:styled-content><\/jats:italic>\u2009&lt;\u20090.00001), respectively. Severe adverse event incidence was similar between the groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Intravitreal anti\u2010vascular endothelial growth factor injections were safe and effective for macular oedema secondary to central retinal vein occlusion. The efficacy was rapid and robust. Further trials are needed to determine the detailed indications and therapeutic regimens of anti\u2010vascular endothelial growth factor treatments.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ceo.12286","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T14:26:56Z","timestamp":1386858416000},"page":"637-649","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta\u2010analysis"],"prefix":"10.1111","volume":"42","author":[{"given":"Shuangwen","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Shanghai First People's Hospital Shanghai Jiaotong University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianping","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Nutrition School of Medicine Shanghai Jiaotong University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Shanghai First People's Hospital Shanghai Jiaotong University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.07.017"},{"key":"e_1_2_5_3_1","first-page":"443","volume-title":"Retinal Vascular Disease","author":"Hansen LL","year":"2007"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000320076"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2011.02713.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283459737"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130537006"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.01.060"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150488006"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30849-4"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.234"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.032"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.11.011"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2007.01144.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412013312203"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100120068012"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007325.pub2"},{"key":"e_1_2_5_18_1","first-page":"274","article-title":"Antiangiogenic drugs in the management of ocular disease: focus on antivascular endothelial growth factor","volume":"4","author":"Sassa Y","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.06.006"},{"key":"e_1_2_5_21_1","volume-title":"Review Manager (RevMan) [Computer Program]. Version 5.2","year":"2012"},{"key":"e_1_2_5_22_1","unstructured":"BrozekJ OxmanA Sch\u00fcnemannH.GRADEpro. [Computer program]. Version 3.2 for Windows.2008."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_5_24_1","first-page":"1023","article-title":"Vascular endothelial growth factor Trap\u2010Eye for macular edema secondary to central retinal vein occlusion: six\u2010month results of the phase 3 COPERNICUS study","volume":"1195","author":"Boyer D","year":"2012","journal-title":"Ophthalmology"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.02.038"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.01.022"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.06.037"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-301504"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.03.028"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.14"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181f4420d"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200410000-00002"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00021.2004"},{"key":"e_1_2_5_36_1","first-page":"4048","article-title":"Photoreceptor function in eyes with macular edema","volume":"41","author":"Lardenoye CW","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2008.11.011"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c2459"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2010.513090"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1486-7"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fceo.12286","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.12286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:08:21Z","timestamp":1696363701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.12286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/ceo.12286"],"URL":"https:\/\/doi.org\/10.1111\/ceo.12286","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]},"assertion":[{"value":"2013-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}